Description

Ziprasidone Capsules

Healthy Inc is a specialized global supplier and exporter of advanced central nervous system (CNS) and psychiatric therapeutics. We provide high-purity Ziprasidone Capsules (20 mg / 40 mg / 60 mg / 80 mg), manufactured in WHO–GMP certified oral solid dosage facilities. This “Second-Generation Atypical Antipsychotic” is a high-value export to psychiatric hospitals, behavioral health centers, and government health ministries in Africa, LATAM, and Southeast Asia, serving as a frontline, metabolically safe intervention for Schizophrenia and acute Bipolar I manic or mixed episodes.

Product Overview

This formulation contains Ziprasidone (as Ziprasidone Hydrochloride Monohydrate), a potent benzisothiazolyl atypical antipsychotic agent.

The “Receptor-Optimized & Metabolically Safe” Specialist:

• Mechanism (D2 & 5-HT2A Antagonism): Ziprasidone exerts its primary antipsychotic efficacy by acting as a highly potent antagonist at both the Dopamine D2 and Serotonin 5-HT2A receptors. Blocking D2 receptors in the mesolimbic pathway mitigates the “positive” symptoms of schizophrenia (hallucinations, delusions), while 5-HT2A antagonism in the mesocortical pathway helps alleviate “negative” symptoms (apathy, flat affect) and reduces extrapyramidal side effects.
• 5-HT1A Agonism (The Anxiolytic Edge): Uniquely, it also acts as an agonist at the 5-HT1A receptor and weakly inhibits the reuptake of serotonin and norepinephrine, giving it an intrinsic antidepressant and anxiolytic profile that benefits schizoaffective and bipolar patients.
• The Metabolic Advantage: Unlike its competitors, Ziprasidone causes virtually zero weight gain, does not elevate fasting blood glucose, and actually tends to lower cholesterol and triglyceride levels. This makes it the drug of choice for patients with existing obesity, diabetes, or severe cardiovascular risk factors.

Product Composition & Strength

We supply this product as a Hard Gelatin Capsule, packed in moisture-resistant Alu-Alu or Alu-PVC blister strips.

*Pack Sizes: 10×10 Alu-PVC Blisters or Bulk Jars of 500/1000 Capsules for institutional psychiatric dispensing.

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers and Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Particle Size Optimization: Ziprasidone exhibits low aqueous solubility. Our API undergoes strict micronization protocols to ensure optimal particle size distribution. This guarantees maximum, uniform dissolution within the gastrointestinal tract, meeting strict pharmacopeial bioavailability standards.
• Blend Uniformity: Advanced high-shear granulation is utilized for the lower-dose (20mg) capsules to ensure absolute content uniformity, preventing accidental under-dosing which could trigger a psychiatric relapse.

Therapeutic Indications (Human Use)

Indicated for the management of severe psychotic and bipolar disorders:

• Schizophrenia: Acute and maintenance treatment of schizophrenia in adults.
• Bipolar I Disorder: Acute treatment of manic or mixed episodes associated with bipolar I disorder (with or without psychotic features). Often used as maintenance therapy as an adjunct to lithium or valproate.

Dosage & Administration

Recommended Dosage (Strictly as per Psychiatrist):

• Administration (CRITICAL FOOD REQUIREMENT): MUST be taken with a meal of at least 500 calories. Taking Ziprasidone on an empty stomach reduces its absorption by up to 50%, completely nullifying its clinical effectiveness and leading to rapid psychotic relapse.
• Schizophrenia (Adults): Typically initiated at 20 mg twice daily with food. Can be titrated up to a maximum of 80 mg twice daily.
• Bipolar Mania (Adults): Often requires faster titration, starting at 40 mg twice daily with food, increasing to 60 mg or 80 mg twice daily by day 2.

Safety Warnings (CRITICAL):

• BLACK BOX WARNING (Elderly Dementia): Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (primarily from cardiovascular or infectious events). Ziprasidone is not approved for the treatment of patients with dementia-related psychosis.
• QTc Interval Prolongation: Ziprasidone causes a dose-related prolongation of the QTc interval. It is strictly contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other drugs known to prolong the QT interval.
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Rare, but potentially fatal, multiorgan hypersensitivity reactions have been reported.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for CNS and Psychiatric Medicines, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.